ArticleAmerican journal of ophthalmology case reports2017
Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy.
Article in American journal of ophthalmology case reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Efficacy and safety of tocilizumab in the treatment of Graves' orbitopathy: a systematic review and meta-analysis.BMC endocrine disorders · 2026Pooled it
- The role of monoclonal antibodies against IL-6 or IL-6R in the treatment of thyroid eye disease.Reviews in endocrine & metabolic disorders · 2026Review
- Article
- Tocilizumab use for optic nerve compression in thyroid eye disease: a prospective longitudinal cohort.International ophthalmology · 2024Article
- Article
- Current concepts regarding Graves' orbitopathy.Journal of internal medicine · 2022Review
- Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management.Indian journal of ophthalmology · 2022Review
- Tocilizumab use in pediatric thyroid eye disease: First documented case.American journal of ophthalmology case reports · 2022Article
- Cytokines in Thyroid-Associated Ophthalmopathy.Journal of immunology research · 2022Review
- Steroid-Resistant Graves' Orbitopathy Treated with Tocilizumab in Real-World Clinical Practice: A 9-Year Single-Center Experience.Journal of clinical medicine · 2021Article
- Novel Approaches for Immunosuppression in Graves' Hyperthyroidism and Associated Orbitopathy.European thyroid journal · 2020Article
- Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients.Journal of clinical medicine · 2020Article
- Current Understanding of the Progression and Management of Thyroid Associated Orbitopathy: A Systematic Review.Ophthalmology and therapy · 2020Review
- New insights into the pathogenesis and nonsurgical management of Graves orbitopathy.Nature reviews. Endocrinology · 2020Review
- Thyroid Eye Disease: How A Novel Therapy May Change The Treatment Paradigm.Therapeutics and clinical risk management · 2019Review
- The Two-Faced Cytokine IL-6 in Host Defense and Diseases.International journal of molecular sciences · 2018Review
- Active Moderate-to-Severe Graves' Orbitopathy in a Patient With Type 2 Diabetes Mellitus and Vascular Complications.Frontiers in endocrinology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo describe the effect of tocilizumab in two patients with thyroid associated orbitopathy (TAO). OBSERVATIONS: We present two patients with TAO who could not tolerate corticosteroids and had a reduction in clinical and laboratory markers of inflammatory activity with subsequent tocilizumab therapy. CONCLUSIONS AND IMPORTANCE: The IL-6 receptor antibody tocilizumab is a promising candidate for the treatment of TAO because it selectively targets a key inflammatory mediator and has a favorable side effect profile. Our report demonstrates that tocilizumab can achieve further reduction in inflammatory activity after treatment with corticosteroids. Importantly, we and others have observed a decrease in the level of thyroid stimulating immunoglobulin (TSI) with tocilizumab treatment. This suggests an upstream effect in the inflammatory cascade. Although the impact of tocilizumab on long-term outcome is unknown at this time, we believe that early disruption of the inflammatory process may prevent late complications and decrease the need for rehabilitative surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.